Sage Group News

Sage Represents Cancer Prevention Pharmaceuticals: A Late Stage, $Billion Orphan Product Opportunity

Sage’s client, Cancer Prevention Pharmaceuticals (“CPP”;,is a late clinical stage company developing a unique, oral, fixed dose combination drug (CPP-1X/sul) to treat Familial Adenomatous Polyposis (FAP), an inherited disorder characterized by cancer of the large intestine (colon) and rectum. People with the classic type of FAP may begin to develop multiple noncancerous (benign) growths (polyps) in the colon as early as their teenage years. Unless the colon and associated parts of the GI tract are resected, these polyps will become malignant (cancerous). The average age at which an individual develops colon cancer, without constant surveillance and surgical intervention,